ABC | Volume 110, Nº4, April 2018

Original Article Cartolano et al LAP and lipoprotein size Arq Bras Cardiol. 2018; 110(4):339-347 1. WorldHealthOrganization. (WHO). Prevention of cardiovascular disease – Guidelines for assessment andmanagement of cardiovascular risk. Geneva; 2007. [Series of Technical Reports]. 2. Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids. 2015;2015:971453. doi: 10.1155/2015/971453. 3. Sviridov D, Nestel P. Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis. 2002;161(12):245-54. doi: https:// doi.org/10.1016/S0021-9150 (01)00677-3. 4. Hirayama S, Miida T. Small dense LDL: an emerging risk factor for cardiovascular disease. Clin Chim Acta. 2012 Dec 24;414:215-24. doi: 10.1016/j.cca.2012.09.010. 5. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients. 2013;5(3):928-48. doi: 10.3390/nu5030928. 6. Camont L, Lhomme M, Rached F, Le Goff W, Negre-Salvavyre A, Salvavrey R, et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol. 2013;33(12):2715-23. doi: 10.1161/ATVBAHA.113.301468. 7. Woudberg NJ, Goedecke JH, Blackhurst D, Frias M, James R, Opie LH, et al. Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution. Lipids Health Dis. 2016 May 11;15:92. doi: 10.1186/s12944-016-0257-9. 8. Kahn HS, Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr. 2003;78(5):928-34. PMID: 14594778. 9. Ioachimescu AG, Brennan DM, Hoar BM, Hoogwerf BJ. The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obesity (Silver Spring). 2010;18(9):1836-44. doi: 10.1038/oby.2009.453. 10. KahnHS.The“lipidaccumulationproduct”performsbetterthanthebodymass indexforrecognizingcardiova scularrisk:apopulation-basedcomparison.BMC CardiovascDisord. 2005 Sep 8;5:26. doi: 10.1186/1471-2261-5-26. 11. Kahn HS. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care. 2006;29(1):151- 3. doi: https://doi.org/10.2337/diacare.29.01.06.dc05-1805. 12. Oh JY, Sung YA, Lee HJ. The lipid accumulation product as a useful index for identifying abnormal glucose regulation in young Korean women. Diabet Med. 2013;30(4):436-42. doi: 10.1111/dme.12052. 13. Tankó LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005;111(15):1883-90. doi: 10.1161/01.CIR.0000161801.65408.8D. 14. Lwow F, Jedrzejuk D, Milewicz A, Szmigiero L. Lipid accumulation product (LAP) as a criterion for the identification of the healthy obesity phenotype in postmenopausal women. ExpGerontol. 2016 Sep;82:81-7. doi: 10.1016/j. exger.2016.06.007. 15. Nascimento JX, Chein MB, Sousa RM, Ferreira AS, Navarro PA, Brito LM. Importance of lipid accumulation product index as marker of CVD risk in PCOSwomen. Lipids HealthDis. 2015 Jun 24;14:62. doi: 10.1186/s12944- 015-0061-y. 16. Macut D, Tziomalos K, Antic-Bozic I, Bjekic-Macut J, Katsikis I, Papadakis E, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod. 2016 Jun;31(6):1347-53. doi: 10.1093/humrep/dew076. 17. Costa EC, Ferezini De Sá JC, Soares EM, Lemos TM, Maranhão TM, Azevedo GD. Evaluation of cardiovascular risk by the LAP index in non-obese patients withpolycysticovarysyndrome.ArqBrasEndocrinolMetab.2010;54(7):630- 5. doi: http://dx.doi.org/10.1590/S0004-27302010000700007. 18. Wehr E, Pilz S, Boehm BO, März W, Obermayer-Pietsch B. The lipid accumulation product is associated with increased mortality in normal weight postmenopausal women. Obesity (Silver Spring). 2011;19(9):1873- 80. doi: 10.1038/oby.2011.42. 19. Maturana MA, Moreira RM, Spritzer PM. Lipid accumulation product (LAP) is related to androgenicity and cardiovascular risk factors in postmenopausal women.Maturitas.2011;70(4):395-9.doi:10.1016/j.maturitas.2011.09.012. 20. Pontes AG, Rehme MF, Martins AM, Micussi MT, Maranhão TM, PimentaWP, et al. Insulin resistance in women with polycystic ovary syndrome: relationship with anthropometric and biochemical variables. Rev Bras Ginecol Obstet. 2012;34(2):74-9.doi :http://dx.doi.org/10.1590/S0100-72032012000200006. 21. D´Agostino RB, Vasan RS, Pecina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: The FraminghamHeart Study. Circulation. 2008;117(6):743-53. doi: 10.1161/ CIRCULATIONAHA.107.699579. 22. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women 2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-62. doi: 10.1161/CIR.0b013e31820faaf8. Erratumin:Circulation.2011;123(22):e624;Circulation.2011;124(16):e427. 23. FriedewaldWT, Levy RI, FredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. PMID: 4337382. 24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration inman. Diabetologia. 1985;28(7):412-9. PMID: 3899825. 25. Koba S, Hirano T, Kondo T, Shibata M, Suzuki H, Murakami M, et al. Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart disease. Am Heart J. 2002;144(6):1026-35. doi: 10.1067/mhj.2002.126119. References Sources of Funding This study was funded by INCT-FCX, NAP-FCX-USP, FAPESP and CNPq. Study Association This article is part of the thesis of master submitted by Flavia De Conti Cartolano, from Universidade de São Paulo. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Hospital Universitário da Universidade de São Paulo under the protocol number 1126/11 and Faculdade de Saúde Pública da Universidade de São Paulo sob o número 2264. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 346